IXICO shares rise 4% as company gives an upbeat assessment of prospects

IXICO shares rose 4% to 11.13p after the neuroscience imaging group said it enters 2026 with strong momentum, driven by a 27% increase in its order book to £17.7m since the September year-end and a sharp rise in new contract wins. Management highlighted strengthening demand across Alzheimer’s, Huntington’s and blood-based biomarker work—citing an Alzheimer’s UK tally of 138 drugs in testing, up 9%—and expects growth from an expanded imaging-focused CRO role and broader adoption of its AI-driven biomarker platform. Full-year results showed revenue up 13% to £6.5m, gross margin improving to 49%, EBITDA losses narrowed to £1.3m and cash of £3.5m after a £3.7m fundraise, underpinning the board’s confidence despite cautious biopharma spending.

Analysis

IXICO shares rose 4% to 11.13p after management said the group is entering 2026 with strong momentum, driven by a 27% increase in the order book from £13.8m at the September year‑end to £17.7m by end‑November and a sharp rise in new contract wins. Demand has strengthened across Alzheimer’s, Huntington’s and blood‑based biomarker work despite broader biopharma caution, and the company cites an Alzheimer’s UK tally of 138 drugs in testing (a 9% year‑on‑year increase) as evidence of accelerating research activity.

Management expects growth from expanding IXICO’s imaging‑focused CRO role and broader adoption of its AI‑driven biomarker platform, positioning the business to capture higher‑value work as drug developers seek imaging and AI solutions. Full‑year results showed revenue up 13% to £6.5m, gross margin improved to 49% and EBITDA losses narrowed to £1.3m, indicating improving unit economics while still loss‑making.

Cash rose to £3.5m after a £3.7m fundraise, which reduces immediate liquidity risk but leaves limited runway if growth stalls; the upbeat commentary and order‑book expansion support a constructive outlook, while continued conversion of backlog and sustained margin improvement are critical to de‑risk the story.

Key Decisions for Investors

• Consider selective accumulation given the 27% order‑book increase to £17.7m, 13% revenue growth and margin improvement, but size positions conservatively because IXICO remains EBITDA‑loss making (£1.3m) with modest cash (£3.5m)
• Monitor quarterly contract‑win cadence, backlog conversion rates and any guidance on cash runway as primary catalysts before increasing exposure
• Employ hedges or stop‑losses to protect capital against sector spending volatility and reassess bullish positions if management fails to sustain margin gains or reach EBITDA breakeven